A Phase 3 interventional study of Bevacizumab and Durvalumab in Advanced Ovarian Cancer, sponsored by AstraZeneca. Active, not recruiting at 214 sites in 20 countries. Open to female participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-07-07.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing durvalumab in Ovarian Neoplasms — 2 open to participants now, 6 under way, 1 of them phase 3. durvalumab · Ovarian Neoplasms.
Among the 14 studies testing durvalumab in Ovarian Neoplasms, this one has the largest enrollment, is the only one that started in 2019, is the only one in phase 3, and was the 11th registered.
3,387 studies on the registry are indexed under Ovarian Neoplasms; 792 are open to participants now.
Browse Ovarian Neoplasms studies →2 of the 14 studies testing durvalumab in Ovarian Neoplasms are open now, in 1 country. Recruiting first, the newest first:
Second Affiliated Hospital of Guangzhou Medical University · Sites in China
Ages 18–70
British Columbia Cancer Agency
Ages 18+ · Women only
By country, each count listing its studies:
durvalumab: first FDA approval 2017 (IMFINZI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 605 Ovarian Neoplasms studies recruiting now, 442 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.
This study: 18 Years to 130 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, durvalumab is the treatment under test here. Read study by study →
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 8 · Phase 3 1
First in 2013; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,407 is above the median of 54 across 2,552 interventional studies indexed under Ovarian Neoplasms.
Median enrollment 85 across the 14 interventional studies. Of the 6 that completed or were terminated, 4 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 14 have an industry lead sponsor. The 9 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
70 studies in Ovarian Neoplasms by AstraZeneca: 8 open now, 20 under way, 6 of them phase 3. Of 45 finished, 15 (33%) have results posted.
Among the 70 studies in Ovarian Neoplasms by AstraZeneca, this one has the largest enrollment of the 47 interventional ones that give a count, is one of 2 that started in 2019, is one of 11 in phase 3, reaches primary completion later than 4 of the 19 other live ones, and was the 42nd registered.
AstraZeneca’s Ovarian Neoplasms studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 14 studies testing durvalumab in Ovarian Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 70 in Ovarian Neoplasms:
This tab as a report to print or save as PDF → With an account.
This is a Phase III randomised, double-blind, multi-centre study to evaluate the efficacy and safety of durvalumab in combination with standard of care platinum based chemotherapy and bevacizumab followed by maintenance durvalumab and bevacizumab or durvalumab, bevacizumab and olaparib in patients with newly diagnosed advanced ovarian cancer.
Eligible patients will be those patients with newly diagnosed, histologically confirmed advanced (Fédération Internationale de Gynécologie et d'Obstétrique [FIGO] Stage III-IV) ovarian, primary peritoneal cancer and/or fallopian-tube cancer. All patients should be candidates for cytoreductive surgery which could be conducted as immediate upfront primary surgery following diagnosis or can be conducted after initiation of platinum based neoadjuvant chemotherapy. All patients should be eligible to start first line platinum based chemotherapy in combination with bevacizumab.
The study aims to evaluate the efficacy and safety of standard of care (SoC) platinum-based chemotherapy and bevacizumab followed by maintenance bevacizumab either as monotherapy, or in combination with durvalumab, or in combination with durvalumab and olaparib. Therefore, this study aims to see which combination allows patients to live longer without the cancer coming back or getting worse. The study is also looking to see which combination makes patients live longer and how the treatment and the cancer affects their quality of life.
Key Inclusion Criteria:
Female patients with newly diagnosed, confirmed, advanced (Stage III-IV) high grade epithelial ovarian cancer including high grade serious, high grade endometriod, clear cell ovarian cancer or carcinosarcoma, primary peritoneal cancer and / or fallopian-tube cancer
Key Exclusion Criteria:
Non-epithelial ovarian cancer, borderline tumors, low grade epithelial tumors or mucinous histology
History of another primary except for:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platinum-based chemotherapy in combination with bevacizumab and durvalumab placebo (saline IV infusion) followed by maintenance bevacizumab, durvalumab placebo (saline IV infusion) and olaparib placebo (tablets).
Drug: Bevacizumab · Drug: Placebo olaparib · Drug: Durvalumab placebo · Drug: Carboplatin+Paclitaxel
Platinum-based chemotherapy in combination with bevacizumab and durvalumab followed by maintenance bevacizumab, durvalumab and olaparib placebo.
Drug: Bevacizumab · Drug: Durvalumab · Drug: Placebo olaparib · Drug: Carboplatin+Paclitaxel
Platinum-based chemotherapy in combination with bevacizumab and durvalumab followed by maintenance bevacizumab, durvalumab and olaparib.
Drug: Bevacizumab · Drug: Durvalumab · Drug: Olaparib · Drug: Carboplatin+Paclitaxel
Platinum-based chemotherapy in combination with bevacizumab and durvalumab followed by maintenance bevacizumab, durvalumab and olaparib. Bevacizumab is optional according to local practice.
Drug: Bevacizumab · Drug: Durvalumab · Drug: Olaparib · Drug: Carboplatin+Paclitaxel
Bevacizumab by intravenous infusion. In tBRCAm cohort bevacizumab is optional according to local practice.
Durvalumab by intravenous infusion
Olaparib tablets
Placebo tablets to match olaparib
Matching placebo for intravenous infusion
Drug pages: Carboplatin · Paclitaxel
Standard of care chemotherapy
Progression-free Survival (PFS) by Investigator Assessment Using Modified RECIST 1.1 - Full Analysis Set
To determine the efficacy of durvalumab in combination with platinum based chemotherapy and bevacizumab and continued as maintenance in combination with bevacizumab and olaparib versus SoC platinum based chemotherapy in combination with bevacizumab by assessment of PFS (using investigator assessment according to Response Evaluation Criteria in Solid Tumours version 1.1 \[RECIST 1.1\]) in the first line treatment of patients with newly diagnosed advanced ovarian cancer. Per MTP, the comparison of SoC+D+O v SoC in the Non-tbRCAm patients is a primary endpoint. SoC+D v SoC is reported separately as a secondary endpoint. Results for tBRCAm SoC+D+O are not presented as this was prespecified to be assessed only in the Non-tBRCAm patients.
Time frame: At baseline, within 3 weeks of last dose of chemotherapy, then every 12 weeks for 3 years and thereafter every 24 weeks. Assessed until primary analysis - (05DEC2022 for Global cohort, 17MAR2025 for China cohort) - upto 46 months
Progression-free Survival (PFS) by Investigator Assessment Using Modified RECIST 1.1 - (Full Analysis Set, HRD Positive)
To determine the efficacy of durvalumab and olaparib assessed by PFS in the first line treatment of patients with newly diagnosed advanced ovarian cancer. Per MTP, the comparison of SoC+D+O v SoC in the Non-tBRCAm HRD positve population is a primary endpoint. SoC+D v SoC is reported separately as a secondary endpoint. Results for tBRCAm SoC+D+O are not presented as as this was prespecified to be assessed only in the Non-tBRCAm patients.
Time frame: At baseline, within 3 weeks of last dose of chemotherapy, then every 12 weeks for 3 years and thereafter every 24 weeks. Assessed until DCO1 - (05DEC2022 for Global cohort, 17MAR2025 for China cohort) - upto 46 months
Progression-free Survival (PFS) by Investigator Assessment Using Modified RECIST 1.1 - Full Analysis Set
To determine the efficacy of durvalumab assessed by PFS in the first line treatment of patients with newly diagnosed advanced ovarian cancer. Per MTP, the comparison of SoC+D v SoC is a secondary endpoint. SoC+D+O v SoC is reported separately as a primary endpoint. Results for tBRCAm SoC+D+O are not presented as this was prespecified to be assessed only in the Non-tBRCAm patients.
Time frame: At baseline, within 3 weeks of last dose of chemotherapy, then every 12 weeks for 3 years and thereafter every 24 weeks. For global cohort, assessed until DCO2 (18SEP2023) - up to 55 months. For China cohort assessed until DCO1 (17MAR2025) - 46 months.
Overall Survival - Full Analysis Set
To determine the efficacy of durvalumab and olaparib assessed by OS in the first line treatment patients with newly diagnosed advanced ovarian cancer. Overall survival (OS) is defined as the time from randomisation/allocation to death due to any cause regardless of whether the patient withdraws from randomised therapy or receives another anti-cancer therapy. Results for tBRCAm SoC+D+O are not presented as this was prespecified to be assessed only in the Non-tBRCAm patients.
Time frame: Survival assessed every 12 weeks after RECIST 1.1 defined progression. For global cohort, assessed until DCO3 (17MAR2025) - up to 73 months. For China cohort assessed until DCO1 (17MAR2025) - up to 46 months.
Overall Survival - (Full Analysis Set, HRD-positive)
To determine the efficacy of durvalumab and olaparib assessed by OS in the first line treatment patients with newly diagnosed advanced ovarian cancer. Overall survival (OS) is defined as the time from randomisation/allocation to death due to any cause regardless of whether the patient withdraws from randomised therapy or receives another anti-cancer therapy. Results for tBRCAm SoC+D+O are not presented as this was prespecified to be assessed only in the Non-tBRCAm patients.
Time frame: Survival assessed every 12 weeks after RECIST 1.1 defined progression. For global cohort, assessed until DCO3 (17MAR2025) - up to 73 months. For China cohort assessed until DCO1 (17MAR2025) - up to 46 months.
Time to Second Progression or Death Based on Local Standard Clinical Practice (PFS2) - Full Analysis Set
To assess the efficacy of durvalumab and olaparib in terms of PFS2 in the first line treatment of patients with newly diagnosed advanced ovarian cancer. Time to second progression or death (PFS2) is defined as the time from the date of randomisation/allocation to the earliest of the progression event subsequent to first subsequent therapy or death. Results for tBRCAm SoC+D+O are not presented as this was prespecified to be assessed only in the Non-tBRCAm patients.
Time frame: Assessed every 12 weeks after RECIST 1.1 defined progression. For global cohort, assessed until DCO3 (17MAR2025) - up to 73 months. For China cohort assessed until DCO1 (17MAR2025) - 46 months.
Time to Second Progression or Death Based on Local Standard Clinical Practice (PFS2) - (Full Analysis Set, HRD-positive)
To assess the efficacy of durvalumab and olaparib in terms of PFS2 in the first line treatment of patients with newly diagnosed advanced ovarian cancer. Time to second progression or death (PFS2) is defined as the time from the date of randomisation/allocation to the earliest of the progression event subsequent to first subsequent therapy or death. Results for tBRCAm SoC+D+O are not presented as this was prespecified to be assessed only in the Non-tBRCAm patients.
Time frame: Assessed every 12 weeks after RECIST 1.1 defined progression. For global cohort, assessed until DCO3 (17MAR2025) - up to 73 months. For China cohort assessed until DCO1 (17MAR2025) - 46 months.
Objective Response Rate Based on Investigator Assessment (Full Analysis Set)
To assess the efficacy of durvalumab and olaparib in terms of ORR (Complete Response + Partial Response) by investigator assessment by modified RECIST 1.1: 1. in all patients with evaluable disease at baseline 2. prior to surgery in those patients planned to have IDS with evaluable disease at baseline. Objective response rate (ORR) is defined similarly for the non-tBRCAm and tBRCAm cohorts as the number (percentage) of patients with at least one investigator-assessed visit response of CR or PR and will be based on a subset of all randomised/allocated patients who have evaluable disease at baseline per the site investigator.
Time frame: At baseline, within 3 weeks of last dose of chemotherapy, then every 12 weeks for 3 years and thereafter every 24 weeks. Up to 55 months for global non-tBRCAm (DCO2 18SEP2023). Up to 46 for Global tBRCAm (DCO1 05DEC2022) and China (DCO1 17MAR2025)
Objective Response Rate Based on Investigator Assessment (Full Analysis Set, HRD-positive)
To assess the efficacy of durvalumab and olaparib in terms of ORR (Complete Response + Partial Response) by investigator assessment by modified RECIST 1.1 1. in all patients with evaluable disease at baseline 2. prior to surgery in those patients planned to have IDS with evaluable disease at baseline. Objective response rate (ORR) is defined similarly for the non-tBRCAm and tBRCAm cohorts as the number (percentage) of patients with at least one investigator-assessed visit response of CR or PR and will be based on a subset of all randomised/allocated patients who have evaluable disease at baseline per the site investigator. This was prespecified to be assessed only in the non-tBRCAm cohort.
Time frame: At baseline, within 3 weeks of last dose of chemotherapy, then every 12 weeks for 3 years and thereafter every 24 weeks. Up to 55 months for global non-tBRCAm (DCO2 18SEP2023). Up to 46 for China (DCO1 17MAR2025)
Duration of Objective Response Based on Investigator Assessments (Full Analysis Set)
To assess the efficacy of durvalumab and olaparib in terms of duration of response (DoR) in the first line treatment of patients with newly diagnosed advanced ovarian cancer. Duration of response (DoR) is defined similarly for the non-tBRCAm and tBRCAm cohorts using the corresponding FAS among patients with a response (CR or PR), as the time from the date of first documented response (i.e., the first time at which the visit response is PR or CR) according to modified RECIST v1.1 as assessed by the investigator until date of documented progression or death in the absence of disease progression. This was prespecified to be assessed only in the Global patients.
Time frame: At baseline, within 3 weeks of last dose of chemotherapy, then every 12 weeks for 3 years and thereafter every 24 weeks. Up to 55 months for global non-tBRCAm (DCO2 18SEP2023). Up to 46 for Global tBRCAm (DCO1 05DEC2022)
Duration of Objective Response Based on Investigator Assessments (Full Analysis Set, HRD-positive)
To assess the efficacy of durvalumab and olaparib in terms of duration of response (DoR) in the first line treatment of patients with newly diagnosed advanced ovarian cancer. Duration of response (DoR) is defined similarly for the non-tBRCAm and tBRCAm cohorts using the corresponding FAS among patients with a response (CR or PR), as the time from the date of first documented response (i.e., the first time at which the visit response is PR or CR) according to modified RECIST v1.1 as assessed by the investigator until date of documented progression or death in the absence of disease progression. This was prespecified to be assessed only in Global Non-tBRCAm patients.
Time frame: At baseline, within 3 weeks of last dose of chemotherapy, then every 12 weeks for 3 years and thereafter every 24 weeks. Up to 55 months for global non-tBRCAm (DCO2 18SEP2023).
Time to First Subsequent Therapy (TFST) - Full Analysis Set
To assess the efficacy of durvalumab and olaparib in terms of TFST in the first line treatment of patients with newly diagnosed advanced ovarian cancer. Time to start of first subsequent therapy or death (TFST) is defined as the time from randomisation/allocation to the earlier of first subsequent therapy start date following study treatment discontinuation, or death. This was prespecified to be assessed only in Non-tBRCAm patients.
Time frame: Assessed every 12 weeks following treatment discontinuation. For global cohort, assessed until DCO3 (17MAR2025) - up to 73 months. For China cohort assessed until DCO1 (17MAR2025) - up to 46 months.
Time to First Subsequent Therapy (TFST) - (Full Analysis Set, HRD-positive)
To assess the efficacy of durvalumab and olaparib in terms of TFST in the first line treatment of patients with newly diagnosed advanced ovarian cancer. Time to start of first subsequent therapy or death (TFST) is defined as the time from randomisation/allocation to the earlier of first subsequent therapy start date following study treatment discontinuation, or death. This was prespecified to be assessed only in Non-tBRCAm patients.
Time frame: Assessed every 12 weeks following treatment discontinuation. For global cohort, assessed until DCO3 (17MAR2025) - up to 73 months. For China cohort assessed until DCO1 (17MAR2025) - up to 46 months.
Time to Second Subsequent Therapy (TSST) - Full Analysis Set
To assess the efficacy of durvalumab and olaparib in terms of TSST in the first line treatment of patients with newly diagnosed advanced ovarian cancer. Time to second subsequent therapy or death (TSST) is defined as the time from randomisation/allocation to the earlier of the second subsequent anti-cancer therapy start date following study treatment discontinuation, or death. This was prespecified to be assessed only in Non-tBRCAm patients.
Time frame: Assessed every 12 weeks following treatment discontinuation. For global cohort, assessed until DCO3 (17MAR2025) - up to 73 months. For China cohort assessed until DCO1 (17MAR2025) - up to 46 months.
Time to Second Subsequent Therapy (TSST) - (Full Analysis Set, HRD-positive)
To assess the efficacy of durvalumab and olaparib in terms of TSST in the first line treatment of patients with newly diagnosed advanced ovarian cancer. Time to second subsequent therapy or death (TSST) is defined as the time from randomisation to the earlier of the second subsequent anti-cancer therapy start date following study treatment discontinuation, or death. This was prespecified to be assessed only in Non-tBRCAm patients.
Time frame: Assessed every 12 weeks following treatment discontinuation. For global cohort, assessed until DCO3 (17MAR2025) - up to 73 months. For China cohort assessed until DCO1 (17MAR2025) - up to 46 months.
Time to Treatment Discontinuation (TDT) - Full Analysis Set
To assess the efficacy of durvalumab and olaparib in terms of TDT in the first line treatment of patients with newly diagnosed advanced ovarian cancer. Time to permanent study treatment discontinuation or death (TDT) is defined as the time from randomisation/allocation to the earlier of the date of permanent study treatment discontinuation or death. This was prespecified to be assessed only in Non-tBRCAm patients.
Time frame: Assessed through study completion, up to 73 months for global non-tBRCAm (DCO3 17MAR2025) and up to 46 months for and China (DCO1 17MAR2025)
Time to Treatment Discontinuation (TDT) - (Full Analysis Set, HRD-positive)
To assess the efficacy of durvalumab and olaparib in terms of TDT in the first line treatment of patients with newly diagnosed advanced ovarian cancer. Time to permanent study treatment discontinuation or death (TDT) is defined as the time from randomisation/allocation to the earlier of the date of permanent study treatment discontinuation or death. This was prespecified to be assessed only in Non-tBRCAm patients.
Time frame: Assessed through study completion, up to 73 months for global non-tBRCAm (DCO3 17MAR2025) and up to 46 months for and China (DCO1 17MAR2025)
Change From Baseline in Physical Function Score of the EORTC-QLQ-C30 and EORTC-QLQ-OV28 Questionnaires - Full Analysis Set
To determine the effects on HRQoL, global health status and ovarian cancer symptoms of the combination of durvalumab and olaparib in the first line treatment of non-tBRCAm patients with newly diagnosed advanced ovarian cancer. The physical functioning score is a score from 0 to 100. Higher scores on the physical functioning score indicate better health status/function. This was prespecified to be assessed only in Global Non-tBRCAm patients.
Time frame: Assessed at week 96.
Change From Baseline in Physical Function Score of the EORTC-QLQ-C30 and EORTC-QLQ-OV28 Questionnaires - (Full Analysis Set, HRD Positive)
To determine the effects on HRQoL, global health status and ovarian cancer symptoms of the combination of durvalumab and olaparib in the first line treatment of non-tBRCAm patients with newly diagnosed advanced ovarian cancer. The physical functioning score is a score from 0 to 100. Higher scores on the physical functioning score indicate better health status/function. This was prespecified to be assessed only in Global Non-tBRCAm patients.
Time frame: Assessed at week 96.
Change From Baseline in Global Health Status/QoL Score of the EORTC-QLQ-C30 and EORTC-QLQ-OV28 Questionnaires - Full Analysis Set
To determine the effects on HRQoL, global health status and ovarian cancer symptoms of the combination of durvalumab and olaparib in the first line treatment of non-tBRCAm patients with newly diagnosed advanced ovarian cancer. The global health status/quality of life (QoL) is a score from 0 to 100. Higher scores on the global health status/QoL indicate better health status/function. This was prespecified to be assessed only in Global Non-tBRCAm patients.
Time frame: Assessed at week 96.
Change From Baseline in Global Health Status/QoL Score of the EORTC-QLQ-C30 and EORTC-QLQ-OV28 Questionnaires - (Full Analysis Set, HRD Positive)
To determine the effects on HRQoL, global health status and ovarian cancer symptoms of the combination of durvalumab and olaparib in the first line treatment of non-tBRCAm patients with newly diagnosed advanced ovarian cancer. The global health status/quality of life (QoL) is a score from 0 to 100. Higher scores on the global health status/QoL indicate better health status/function. This was prespecified to be assessed only in Global Non-tBRCAm patients.
Time frame: Assessed at week 96
Summary of Serum Concentrations (μg/mL) of Durvalumab for Each Treatment - Non-tBRCAm Cohort With Primary Cytoreductive Surgery (Pharmacokinetic Analysis Set)
To characterize the PK of durvalumab in combination with bevacizumab and olaparib. This was prespecified to be assessed only in Global Non-tBRCAm patients.
Time frame: Assessed at Day 85 pre-dose, Day 183 pre-dose and 3 months after last dose of durvalumab.
Summary of Plasma Concentrations (μg/mL) of Olaparib - Non-tBRCAm Cohort With Primary Cytoreductive Surgery (Pharmacokinetic Analysis Set)
To determine olaparib plasma concentrations via sparse sampling for population PK analyses. This was prespecified to be assessed only in Global Non-tBRCAm patients.
Time frame: Assessed on Day 148 post-dose (1-3 hours, 3-6 hours and 6-12 hours)
Summary of ADA Responses During the Study for Durvalumab - Non-tBRCAm Cohort With Primary Cytoreductive Surgery (ADA Analysis Set)
To characterize the immunogenicity of durvalumab in combination with bevacizumab and olaparib. This was prespecified to be assessed only in Global Non-tBRCAm patients.
Time frame: Assessed pre-infusion at Cycle 2, Cycle 4, Cycle 6 and the third cycle of the maintenance phase as well as 3 months after last dose of durvalumab
Overall, 1407 patients were randomised into the study. Global Cohort: 1502 patients screened across 179 sites in 20 countries. 1130 were randomised in the Non-tBRCAm cohort and 154 allocated to the tBRCAm cohort. China Cohort: 134 patients screened across 29 sites; 124 were randomized. 1 patient in the China cohort was randomised prior to Global recruitment closure and hence included in both the Global and China cohort summaries. No patients in the tBRCAm cohort were enrolled from China
| Milestone | Global Non-tBRCAm: SoC | Global Non-tBRCAm: SoC + Durvalumab | Global Non-tBRCAm: SoC + Durvalumab + Olaparib | Global tBRCAm: SoC + Durvalumab + Olaparib | China Non-tBRCAm: SoC | China Non-tBRCAm: SoC + Durvalumab | China Non-tBRCAm: SoC + Durvalumab + Olaparib |
|---|---|---|---|---|---|---|---|
| Started | 378 | 374 | 378 | 154 | 40 | 43 | 41 |
| Completed | 153 | 160 | 172 | 100 | 26 | 31 | 34 |
| Not completed | 225 | 214 | 206 | 54 | 14 | 12 | 7 |
| Withdrew: Death | 201 | 196 | 186 | 46 | 14 | 11 | 7 |
| Withdrew: Withdrawal by subject | 22 | 17 | 20 | 7 | 0 | 1 | 0 |
| Withdrew: Pre-mature site closure and screen failure, | 2 | 1 | 0 | 1 | 0 | 0 | 0 |
To determine the efficacy of durvalumab assessed by PFS in the first line treatment of patients with newly diagnosed advanced ovarian cancer. Per MTP, the comparison of SoC+D v SoC is a secondary endpoint. SoC+D+O v SoC is reported separately as a primary endpoint. Results for tBRCAm SoC+D+O are not presented as this was prespecified to be assessed only in the Non-tBRCAm patients.
| Months | Global Non-tBRCAm: SoC | Global Non-tBRCAm: SoC+D | China Non-tBRCAm: SoC | China Non-tBRCAm: SoC+D |
|---|---|---|---|---|
| Progression-free Survival (PFS) by Investigator Assessment Using Modified RECIST 1.1 - Full Analysis Set | 19.3 (17.9 to 20.4) | 20.6 (18.7 to 22.5) | 17.4 (11.7 to 26.4) | 21.7 (12.4 to NA) |
To determine the efficacy of durvalumab and olaparib assessed by OS in the first line treatment patients with newly diagnosed advanced ovarian cancer. Overall survival (OS) is defined as the time from randomisation/allocation to death due to any cause regardless of whether the patient withdraws from randomised therapy or receives another anti-cancer therapy. Results for tBRCAm SoC+D+O are not presented as this was prespecified to be assessed only in the Non-tBRCAm patients.
| Months | Global Non-tBRCAm: SoC | Global Non-tBRCAm: SoC+D | Global Non-tBRCAm: SoC+D+O | China Non-tBRCAm: SoC | China Non-tBRCAm: SoC+D | China Non-tBRCAm: SoC+D+O |
|---|---|---|---|---|---|---|
| Overall Survival - Full Analysis Set | 49.6 (45.8 to 57.8) | 48.5 (43.6 to 59.0) | 50.5 (45.2 to 65.1) | NA (NA to NA) | 43.2 (34.1 to NA) | NA (NA to NA) |
To determine the efficacy of durvalumab and olaparib assessed by OS in the first line treatment patients with newly diagnosed advanced ovarian cancer. Overall survival (OS) is defined as the time from randomisation/allocation to death due to any cause regardless of whether the patient withdraws from randomised therapy or receives another anti-cancer therapy. Results for tBRCAm SoC+D+O are not presented as this was prespecified to be assessed only in the Non-tBRCAm patients.
| Months | Global Non-tBRCAm: SoC | Global Non-tBRCAm: SoC+D | Global Non-tBRCAm: SoC+D+O | China Non-tBRCAm: SoC | China Non-tBRCAm: SoC+D | China Non-tBRCAm: SoC+D+O |
|---|---|---|---|---|---|---|
| Overall Survival - (Full Analysis Set, HRD-positive) | 66.8 (60.9 to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
To assess the efficacy of durvalumab and olaparib in terms of PFS2 in the first line treatment of patients with newly diagnosed advanced ovarian cancer. Time to second progression or death (PFS2) is defined as the time from the date of randomisation/allocation to the earliest of the progression event subsequent to first subsequent therapy or death. Results for tBRCAm SoC+D+O are not presented as this was prespecified to be assessed only in the Non-tBRCAm patients.
| Months | Global Non-tBRCAm: SoC | Global Non-tBRCAm: SoC+D | Global Non-tBRCAm: SoC+D+O | China Non-tBRCAm: SoC | China Non-tBRCAm: SoC+D | China Non-tBRCAm: SoC+D+O |
|---|---|---|---|---|---|---|
| Time to Second Progression or Death Based on Local Standard Clinical Practice (PFS2) - Full Analysis Set | 32.6 (30.7 to 35.4) | 34.6 (30.2 to 37.7) | 36.9 (32.7 to 41.1) | 27.5 (19.8 to NA) | 28.8 (22.6 to NA) | NA (NA to NA) |
To determine the efficacy of durvalumab in combination with platinum based chemotherapy and bevacizumab and continued as maintenance in combination with bevacizumab and olaparib versus SoC platinum based chemotherapy in combination with bevacizumab by assessment of PFS (using investigator assessment according to Response Evaluation Criteria in Solid Tumours version 1.1 \[RECIST 1.1\]) in the first line treatment of patients with newly diagnosed advanced ovarian cancer. Per MTP, the comparison of SoC+D+O v SoC in the Non-tbRCAm patients is a primary endpoint. SoC+D v SoC is reported separately as a secondary endpoint. Results for tBRCAm SoC+D+O are not presented as this was prespecified to be assessed only in the Non-tBRCAm patients.
| Months | Global Non-tBRCAm: SoC | Global Non-tBRCAm: SoC+D+O | China Non-tBRCAm: SoC | China Non-tBRCAm: SoC+D+O |
|---|---|---|---|---|
| Progression-free Survival (PFS) by Investigator Assessment Using Modified RECIST 1.1 - Full Analysis Set | 19.3 (17.9 to 20.3) | 24.2 (22.7 to 26.8) | 17.4 (11.7 to 26.4) | 26.8 (23.5 to NA) |
To determine the efficacy of durvalumab and olaparib assessed by PFS in the first line treatment of patients with newly diagnosed advanced ovarian cancer. Per MTP, the comparison of SoC+D+O v SoC in the Non-tBRCAm HRD positve population is a primary endpoint. SoC+D v SoC is reported separately as a secondary endpoint. Results for tBRCAm SoC+D+O are not presented as as this was prespecified to be assessed only in the Non-tBRCAm patients.
| Months | Global Non-tBRCAm: SoC | Global Non-tBRCAm: SoC+D+O | China Non-tBRCAm: SoC | China Non-tBRCAm: SoC+D+O |
|---|---|---|---|---|
| Progression-free Survival (PFS) by Investigator Assessment Using Modified RECIST 1.1 - (Full Analysis Set, HRD Positive) | 23 (21.2 to 24.8) | 37.3 (29.8 to NA) | 15.6 (9.3 to 23.9) | 26.8 (23.5 to NA) |
To assess the efficacy of durvalumab and olaparib in terms of PFS2 in the first line treatment of patients with newly diagnosed advanced ovarian cancer. Time to second progression or death (PFS2) is defined as the time from the date of randomisation/allocation to the earliest of the progression event subsequent to first subsequent therapy or death. Results for tBRCAm SoC+D+O are not presented as this was prespecified to be assessed only in the Non-tBRCAm patients.
| Months | Global Non-tBRCAm: SoC | Global Non-tBRCAm: SoC+D | Global Non-tBRCAm: SoC+D+O | China Non-tBRCAm: SoC | China Non-tBRCAm: SoC+D | China Non-tBRCAm: SoC+D+O |
|---|---|---|---|---|---|---|
| Time to Second Progression or Death Based on Local Standard Clinical Practice (PFS2) - (Full Analysis Set, HRD-positive) | 42.4 (38.8 to 58.9) | 51.3 (40.8 to NA) | NA (NA to NA) | NA (NA to NA) | 34.1 (22.2 to NA) | NA (NA to NA) |
To assess the efficacy of durvalumab and olaparib in terms of ORR (Complete Response + Partial Response) by investigator assessment by modified RECIST 1.1: 1. in all patients with evaluable disease at baseline 2. prior to surgery in those patients planned to have IDS with evaluable disease at baseline. Objective response rate (ORR) is defined similarly for the non-tBRCAm and tBRCAm cohorts as the number (percentage) of patients with at least one investigator-assessed visit response of CR or PR and will be based on a subset of all randomised/allocated patients who have evaluable disease at baseline per the site investigator.
| Percentage of participants | Global Non-tBRCAm: SoC | Global Non-tBRCAm: SoC+D | Global Non-tBRCAm: SoC+D+O | Global tBRCAm: SoC+D+O | China Non-tBRCAm: SoC | China Non-tBRCAm: SoC+D | China Non-tBRCAm: SoC+D+O |
|---|---|---|---|---|---|---|---|
| Objective Response Rate Based on Investigator Assessment (Full Analysis Set) | 70.3 | 68.1 | 74.3 | 72.6 | 57.7 | 56.7 | 66.7 |
To assess the efficacy of durvalumab and olaparib in terms of ORR (Complete Response + Partial Response) by investigator assessment by modified RECIST 1.1 1. in all patients with evaluable disease at baseline 2. prior to surgery in those patients planned to have IDS with evaluable disease at baseline. Objective response rate (ORR) is defined similarly for the non-tBRCAm and tBRCAm cohorts as the number (percentage) of patients with at least one investigator-assessed visit response of CR or PR and will be based on a subset of all randomised/allocated patients who have evaluable disease at baseline per the site investigator. This was prespecified to be assessed only in the non-tBRCAm cohort.
| Percentage of participants | Global Non-tBRCAm: SoC | Global Non-tBRCAm: SoC+D | Global Non-tBRCAm: SoC+D+O | China Non-tBRCAm: SoC | China Non-tBRCAm: SoC+D | China Non-tBRCAm: SoC+D+O |
|---|---|---|---|---|---|---|
| Objective Response Rate Based on Investigator Assessment (Full Analysis Set, HRD-positive) | 82.4 | 73.8 | 85.4 | 56.3 | 71.4 | 66.7 |
To assess the efficacy of durvalumab and olaparib in terms of duration of response (DoR) in the first line treatment of patients with newly diagnosed advanced ovarian cancer. Duration of response (DoR) is defined similarly for the non-tBRCAm and tBRCAm cohorts using the corresponding FAS among patients with a response (CR or PR), as the time from the date of first documented response (i.e., the first time at which the visit response is PR or CR) according to modified RECIST v1.1 as assessed by the investigator until date of documented progression or death in the absence of disease progression. This was prespecified to be assessed only in the Global patients.
| Months | Global Non-tBRCAm - SoC | Global Non-tBRCAm - SoC+D | Global Non-tBRCAm - SoC+D+O | Global tBRCAm - SoC+D+O |
|---|---|---|---|---|
| Duration of Objective Response Based on Investigator Assessments (Full Analysis Set) | 16.4 (8.3 to 23.8) | 15.9 (8.4 to 28.3) | 22.3 (12.1 to NA) | NA (24.9 to NA) |
To assess the efficacy of durvalumab and olaparib in terms of duration of response (DoR) in the first line treatment of patients with newly diagnosed advanced ovarian cancer. Duration of response (DoR) is defined similarly for the non-tBRCAm and tBRCAm cohorts using the corresponding FAS among patients with a response (CR or PR), as the time from the date of first documented response (i.e., the first time at which the visit response is PR or CR) according to modified RECIST v1.1 as assessed by the investigator until date of documented progression or death in the absence of disease progression. This was prespecified to be assessed only in Global Non-tBRCAm patients.
| Months | Global Non-tBRCAm - SoC | Global Non-tBRCAm - SoC+D | Global Non-tBRCAm - SoC+D+O |
|---|---|---|---|
| Duration of Objective Response Based on Investigator Assessments (Full Analysis Set, HRD-positive) | 19.4 (12.5 to 47.8) | 19.3 (11.5 to 34.5) | 31.3 (18.4 to NA) |
To assess the efficacy of durvalumab and olaparib in terms of TFST in the first line treatment of patients with newly diagnosed advanced ovarian cancer. Time to start of first subsequent therapy or death (TFST) is defined as the time from randomisation/allocation to the earlier of first subsequent therapy start date following study treatment discontinuation, or death. This was prespecified to be assessed only in Non-tBRCAm patients.
| Months | Global Non-tBRCAm: SoC | Global Non-tBRCAm: SoC+D | Global Non-tBRCAm: SoC+D+O | China Non-tBRCAm: SoC | China Non-tBRCAm: SoC+D | China Non-tBRCAm: SoC+D+O |
|---|---|---|---|---|---|---|
| Time to First Subsequent Therapy (TFST) - Full Analysis Set | 21.6 (20.1 to 23.4) | 21.9 (19.8 to 23.4) | 26.3 (24.2 to 29.5) | 19.0 (12.4 to 27.6) | 21.7 (15.6 to NA) | NA (NA to NA) |
To assess the efficacy of durvalumab and olaparib in terms of TFST in the first line treatment of patients with newly diagnosed advanced ovarian cancer. Time to start of first subsequent therapy or death (TFST) is defined as the time from randomisation/allocation to the earlier of first subsequent therapy start date following study treatment discontinuation, or death. This was prespecified to be assessed only in Non-tBRCAm patients.
| Months | Global Non-tBRCAm: SoC | Global Non-tBRCAm: SoC+D | Global Non-tBRCAm: SoC+D+O | China Non-tBRCAm: SoC | China Non-tBRCAm: SoC+D | China Non-tBRCAm: SoC+D+O |
|---|---|---|---|---|---|---|
| Time to First Subsequent Therapy (TFST) - (Full Analysis Set, HRD-positive) | 25.8 (23.5 to 30.9) | 29.0 (25.1 to 39.2) | 41.4 (33.2 to 59.2) | 17.9 (11.7 to NA) | 34.1 (16.8 to NA) | NA (NA to NA) |
To assess the efficacy of durvalumab and olaparib in terms of TSST in the first line treatment of patients with newly diagnosed advanced ovarian cancer. Time to second subsequent therapy or death (TSST) is defined as the time from randomisation/allocation to the earlier of the second subsequent anti-cancer therapy start date following study treatment discontinuation, or death. This was prespecified to be assessed only in Non-tBRCAm patients.
| Months | Global Non-tBRCAm: SoC | Global Non-tBRCAm: SoC+D | Global Non-tBRCAm: SoC+D+O | China Non-tBRCAm: SoC | China Non-tBRCAm: SoC+D | China Non-tBRCAm: SoC+D+O |
|---|---|---|---|---|---|---|
| Time to Second Subsequent Therapy (TSST) - Full Analysis Set | 33.1 (31.6 to 36.6) | 34.9 (31.8 to 37.8) | 38.5 (34.6 to 42.1) | NA (NA to NA) | 30.6 (22.2 to NA) | NA (NA to NA) |
To assess the efficacy of durvalumab and olaparib in terms of TSST in the first line treatment of patients with newly diagnosed advanced ovarian cancer. Time to second subsequent therapy or death (TSST) is defined as the time from randomisation to the earlier of the second subsequent anti-cancer therapy start date following study treatment discontinuation, or death. This was prespecified to be assessed only in Non-tBRCAm patients.
| Months | Global Non-tBRCAm: SoC | Global Non-tBRCAm: SoC+D | Global Non-tBRCAm: SoC+D+O | China Non-tBRCAm: SoC | China Non-tBRCAm: SoC+D | China Non-tBRCAm: SoC+D+O |
|---|---|---|---|---|---|---|
| Time to Second Subsequent Therapy (TSST) - (Full Analysis Set, HRD-positive) | 46.8 (39.5 to 60.0) | 48.4 (41.8 to NA) | NA (NA to NA) | NA (NA to NA) | 34.1 (22.2 to NA) | NA (NA to NA) |
To assess the efficacy of durvalumab and olaparib in terms of TDT in the first line treatment of patients with newly diagnosed advanced ovarian cancer. Time to permanent study treatment discontinuation or death (TDT) is defined as the time from randomisation/allocation to the earlier of the date of permanent study treatment discontinuation or death. This was prespecified to be assessed only in Non-tBRCAm patients.
| Months | Global Non-tBRCAm: SoC | Global Non-tBRCAm: SoC+D | Global Non-tBRCAm: SoC+D+O | China Non-tBRCAm: SoC | China Non-tBRCAm: SoC+D | China Non-tBRCAm: SoC+D+O |
|---|---|---|---|---|---|---|
| Time to Treatment Discontinuation (TDT) - Full Analysis Set | 18.4 (17.1 to 19.7) | 17.5 (15.2 to 19.4) | 20.4 (18.5 to 21.7) | 14.8 (10.4 to 23.0) | 14.5 (9.0 to 22.4) | 22.0 (15.4 to 26.1) |
To assess the efficacy of durvalumab and olaparib in terms of TDT in the first line treatment of patients with newly diagnosed advanced ovarian cancer. Time to permanent study treatment discontinuation or death (TDT) is defined as the time from randomisation/allocation to the earlier of the date of permanent study treatment discontinuation or death. This was prespecified to be assessed only in Non-tBRCAm patients.
| Months | Global Non-tBRCAm: SoC | Global Non-tBRCAm: SoC+D | Global Non-tBRCAm: SoC+D+O | China Non-tBRCAm: SoC | China Non-tBRCAm: SoC+D | China Non-tBRCAm: SoC+D+O |
|---|---|---|---|---|---|---|
| Time to Treatment Discontinuation (TDT) - (Full Analysis Set, HRD-positive) | 22.0 (20.5 to 24.9) | 22.3 (19.4 to 24.3) | 24.7 (21.9 to 27.5) | 15.7 (9.2 to 24.0) | 20.0 (11.8 to NA) | 21.8 (14.6 to 26.1) |
To determine the effects on HRQoL, global health status and ovarian cancer symptoms of the combination of durvalumab and olaparib in the first line treatment of non-tBRCAm patients with newly diagnosed advanced ovarian cancer. The physical functioning score is a score from 0 to 100. Higher scores on the physical functioning score indicate better health status/function. This was prespecified to be assessed only in Global Non-tBRCAm patients.
| Score on a scale | Global Non-tBRCAm: SoC | Global Non-tBRCAm: SoC+D | Global Non-tBRCAm: SoC+D+O |
|---|---|---|---|
| Change From Baseline in Physical Function Score of the EORTC-QLQ-C30 and EORTC-QLQ-OV28 Questionnaires - Full Analysis Set | 6.3 ± 1.30 | 3.3 ± 1.25 | 3.0 ± 1.31 |
To determine the effects on HRQoL, global health status and ovarian cancer symptoms of the combination of durvalumab and olaparib in the first line treatment of non-tBRCAm patients with newly diagnosed advanced ovarian cancer. The physical functioning score is a score from 0 to 100. Higher scores on the physical functioning score indicate better health status/function. This was prespecified to be assessed only in Global Non-tBRCAm patients.
| Score on a scale | Global Non-tBRCAm: SoC | Global Non-tBRCAm: SoC+D | Global Non-tBRCAm: SoC+D+O |
|---|---|---|---|
| Change From Baseline in Physical Function Score of the EORTC-QLQ-C30 and EORTC-QLQ-OV28 Questionnaires - (Full Analysis Set, HRD Positive) | 9.8 ± 1.53 | 4.9 ± 1.88 | 7.6 ± 1.61 |
To determine the effects on HRQoL, global health status and ovarian cancer symptoms of the combination of durvalumab and olaparib in the first line treatment of non-tBRCAm patients with newly diagnosed advanced ovarian cancer. The global health status/quality of life (QoL) is a score from 0 to 100. Higher scores on the global health status/QoL indicate better health status/function. This was prespecified to be assessed only in Global Non-tBRCAm patients.
| Score on a scale | Global Non-tBRCAm: SoC | Global Non-tBRCAm: SoC+D | Global Non-tBRCAm: SoC+D+O |
|---|---|---|---|
| Change From Baseline in Global Health Status/QoL Score of the EORTC-QLQ-C30 and EORTC-QLQ-OV28 Questionnaires - Full Analysis Set | 6.3 ± 1.23 | 3.8 ± 1.33 | 4.6 ± 1.19 |
To determine the effects on HRQoL, global health status and ovarian cancer symptoms of the combination of durvalumab and olaparib in the first line treatment of non-tBRCAm patients with newly diagnosed advanced ovarian cancer. The global health status/quality of life (QoL) is a score from 0 to 100. Higher scores on the global health status/QoL indicate better health status/function. This was prespecified to be assessed only in Global Non-tBRCAm patients.
| Score on a scale | Global Non-tBRCAm: SoC | Global Non-tBRCAm: SoC+D | Global Non-tBRCAm: SoC+D+O |
|---|---|---|---|
| Change From Baseline in Global Health Status/QoL Score of the EORTC-QLQ-C30 and EORTC-QLQ-OV28 Questionnaires - (Full Analysis Set, HRD Positive) | 8.5 ± 1.75 | 6.3 ± 1.97 | 7.0 ± 1.64 |
To characterize the PK of durvalumab in combination with bevacizumab and olaparib. This was prespecified to be assessed only in Global Non-tBRCAm patients.
| μg/mL | Global Non-tBRCAm: SoC+D | Global Non-tBRCAm: SoC+D+O |
|---|---|---|
| Day 85, pre-dose | 218376.482 ± 40.8 | 207988.974 ± 30.1 |
| Day 148, pre-dose | 237360.027 ± 36.8 | 252257.020 ± 39.9 |
| Follow-up (3 months after last dose of durvalumab.) | 38355.597 ± 112.3 | 25776.441 ± 218.4 |
To determine olaparib plasma concentrations via sparse sampling for population PK analyses. This was prespecified to be assessed only in Global Non-tBRCAm patients.
| μg/mL | Global Non-tBRCAm: SoC+D+O |
|---|---|
| Day 148, 1-3 hours | 5.8563 ± 47.7 |
| Day 148, 3-6 hours | 4.2425 ± 38.4 |
| Day 148, 6-12 hours | 2.5059 ± 44.2 |
To characterize the immunogenicity of durvalumab in combination with bevacizumab and olaparib. This was prespecified to be assessed only in Global Non-tBRCAm patients.
| Number of participants | Global Non-tBRCAm: SoC | Global Non-tBRCAm: SoC+D | Global Non-tBRCAm: SoC+D+O |
|---|---|---|---|
| ADA positive at any visit (ADA Prevalence) | 4 | 2 | 6 |
| Treatment-emergent ADA-positive (ADA incidence) | 1 | 0 | 1 |
| Treatment-boosted ADA | 0 | 0 | 0 |
| Treatment-induced ADA (Positive Post-baseline only) | 1 | 0 | 1 |
| ADA positive at baseline only | 3 | 2 | 5 |
| ADA Positive Post-baseline and Positive at Baseline | 0 | 0 | 0 |
| Persistently positive | 0 | 0 | 0 |
| Transiently positive | 1 | 0 | 1 |
| Neutralising antibody positive at any visit | 0 | 0 | 0 |
Collected over For global cohort, assessed from date of first subject randomised until DCO3 (17MAR2025) - 6 years 1 month. For China cohort assessed from date of first subject randomised until DCO1 (17MAR2025) - 3 years 10 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Global Non-tBRCAm: SoC | 205/378 (54.2%) | 132/376 (35.1%) | 369/376 (98.1%) |
| Global Non-tBRCAm: SoC + Durvalumab | 200/374 (53.5%) | 165/373 (44.2%) | 367/373 (98.4%) |
| Global Non-tBRCAm: SoC + Durvalumab + Olaparib | 193/378 (51.1%) | 152/378 (40.2%) | 372/378 (98.4%) |
| Global tBRCAm: SoC + Durvalumab + Olaparib | 47/154 (30.5%) | 74/153 (48.4%) | 151/153 (98.7%) |
| China Non-tBRCAm: SoC | 14/40 (35%) | 19/40 (47.5%) | 40/40 (100%) |
| China Non-tBRCAm: SoC + Durvalumab | 11/43 (25.6%) | 17/43 (39.5%) | 43/43 (100%) |
| China Non-tBRCAm: SoC + Durvalumab + Olaparib | 7/41 (17.1%) | 22/41 (53.7%) | 41/41 (100%) |
| Event | Global Non-tBRCAm: SoC | Global Non-tBRCAm: SoC + Durvalumab | Global Non-tBRCAm: SoC + Durvalumab + Olaparib | Global tBRCAm: SoC + Durvalumab + Olaparib | China Non-tBRCAm: SoC | China Non-tBRCAm: SoC + Durvalumab | China Non-tBRCAm: SoC + Durvalumab + Olaparib |
|---|---|---|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 5/376 | 3/373 | 12/378 | 1/153 | 1/40 | 1/43 | 5/41 |
| Covid-19Infections and infestations | 4/376 | 7/373 | 8/378 | 1/153 | 0/40 | 0/43 | 3/41 |
| Intestinal obstructionGastrointestinal disorders | 4/376 | 4/373 | 2/378 | 2/153 | 2/40 | 2/43 | 3/41 |
| PneumoniaInfections and infestations | 1/376 | 1/373 | 5/378 | 3/153 | 1/40 | 3/43 | 0/41 |
| Febrile neutropeniaBlood and lymphatic system disorders | 9/376 | 10/373 | 12/378 | 9/153 | 0/40 | 1/43 | 0/41 |
| Hepatic function abnormalHepatobiliary disorders | 0/376 | 0/373 | 1/378 | 0/153 | 2/40 | 0/43 | 1/41 |
| Platelet count decreasedInvestigations | 0/376 | 0/373 | 0/378 | 0/153 | 2/40 | 2/43 | 1/41 |
| ProteinuriaRenal and urinary disorders | 0/376 | 0/373 | 0/378 | 0/153 | 2/40 | 0/43 | 1/41 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 1/376 | 2/373 | 1/378 | 0/153 | 2/40 | 0/43 | 0/41 |
| Upper respiratory tract infectionInfections and infestations | 1/376 | 1/373 | 0/378 | 0/153 | 0/40 | 1/43 | 2/41 |
| Event | Global Non-tBRCAm: SoC | Global Non-tBRCAm: SoC + Durvalumab | Global Non-tBRCAm: SoC + Durvalumab + Olaparib | Global tBRCAm: SoC + Durvalumab + Olaparib | China Non-tBRCAm: SoC | China Non-tBRCAm: SoC + Durvalumab | China Non-tBRCAm: SoC + Durvalumab + Olaparib |
|---|---|---|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 103/376 | 119/373 | 203/378 | 84/153 | 30/40 | 32/43 | 34/41 |
| Neutrophil count decreasedInvestigations | 59/376 | 56/373 | 67/378 | 24/153 | 27/40 | 23/43 | 28/41 |
| White blood cell count decreasedInvestigations | 38/376 | 39/373 | 53/378 | 16/153 | 24/40 | 25/43 | 27/41 |
| NauseaGastrointestinal disorders | 115/376 | 111/373 | 219/378 | 79/153 | 15/40 | 22/43 | 25/41 |
| Platelet count decreasedInvestigations | 31/376 | 38/373 | 51/378 | 19/153 | 19/40 | 21/43 | 25/41 |
| Aspartate aminotransferase increasedInvestigations | 13/376 | 28/373 | 27/378 | 8/153 | 19/40 | 18/43 | 20/41 |
| HypoaesthesiaNervous system disorders | 1/376 | 5/373 | 6/378 | 3/153 | 12/40 | 12/43 | 20/41 |
| Alanine aminotransferase increasedInvestigations | 23/376 | 26/373 | 31/378 | 8/153 | 12/40 | 16/43 | 19/41 |
| VomitingGastrointestinal disorders | 60/376 | 62/373 | 97/378 | 41/153 | 9/40 | 13/43 | 18/41 |
| Weight increasedInvestigations | 8/376 | 9/373 | 9/378 | 8/153 | 16/40 | 18/43 | 8/41 |
1 patient in the China cohort is also included in the Global cohort. Patient is randomised to SoC+Durvalumab.
| Age, Continuous(Years) | Global Non-tBRCAm: SoC | Global Non-tBRCAm: SoC + Durvalumab | Global Non-tBRCAm: SoC + Durvalumab + Olaparib | Global tBRCAm: SoC + Durvalumab + Olaparib | China Non-tBRCAm: SoC | China Non-tBRCAm: SoC + Durvalumab | China Non-tBRCAm: SoC + Durvalumab + Olaparib | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 58.7 ± 9.9 | 58.5 ± 10.8 | 60.2 ± 10.4 | 55.7 ± 10.3 | 58.8 ± 8.6 | 52.8 ± 8.7 | 53.9 ± 9.4 | 58.4 ± 10.4 |
| Age, Customized(Participants) | Global Non-tBRCAm: SoC | Global Non-tBRCAm: SoC + Durvalumab | Global Non-tBRCAm: SoC + Durvalumab + Olaparib | Global tBRCAm: SoC + Durvalumab + Olaparib | China Non-tBRCAm: SoC | China Non-tBRCAm: SoC + Durvalumab | China Non-tBRCAm: SoC + Durvalumab + Olaparib | Total |
|---|---|---|---|---|---|---|---|---|
| >=65 | 110 | 126 | 135 | 37 | 10 | 4 | 5 | 427 |
| <65 | 268 | 248 | 243 | 117 | 30 | 39 | 36 | 981 |
| Sex/Gender, Customized(Participants) | Global Non-tBRCAm: SoC | Global Non-tBRCAm: SoC + Durvalumab | Global Non-tBRCAm: SoC + Durvalumab + Olaparib | Global tBRCAm: SoC + Durvalumab + Olaparib | China Non-tBRCAm: SoC | China Non-tBRCAm: SoC + Durvalumab | China Non-tBRCAm: SoC + Durvalumab + Olaparib | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 378 | 374 | 378 | 154 | 40 | 43 | 41 | 1408 |
| Ethnicity (NIH/OMB)(Participants) | Global Non-tBRCAm: SoC | Global Non-tBRCAm: SoC + Durvalumab | Global Non-tBRCAm: SoC + Durvalumab + Olaparib | Global tBRCAm: SoC + Durvalumab + Olaparib | China Non-tBRCAm: SoC | China Non-tBRCAm: SoC + Durvalumab | China Non-tBRCAm: SoC + Durvalumab + Olaparib | Total |
|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 29 | 20 | 25 | 5 | 0 | 0 | 0 | 79 |
| Not Hispanic or Latino | 345 | 347 | 346 | 149 | 40 | 43 | 41 | 1311 |
| Unknown or Not Reported | 4 | 7 | 7 | 0 | 0 | 0 | 0 | 18 |
| Race/Ethnicity, Customized(Participants) | Global Non-tBRCAm: SoC | Global Non-tBRCAm: SoC + Durvalumab | Global Non-tBRCAm: SoC + Durvalumab + Olaparib | Global tBRCAm: SoC + Durvalumab + Olaparib | China Non-tBRCAm: SoC | China Non-tBRCAm: SoC + Durvalumab | China Non-tBRCAm: SoC + Durvalumab + Olaparib | Total |
|---|---|---|---|---|---|---|---|---|
| AMERICAN INDIAN OR ALASKA NATIVE | 4 | 4 | 1 | 1 | 0 | 0 | 0 | 10 |
| ASIAN | 55 | 52 | 47 | 45 | 40 | 43 | 41 | 323 |
| BLACK OR AFRICAN AMERICAN | 3 | 3 | 4 | 1 | 0 | 0 | 0 | 11 |
| MISSING | 1 | 6 | 1 | 0 | 0 | 0 | 0 | 8 |
| NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| OTHER | 23 | 16 | 19 | 1 | 0 | 0 | 0 | 59 |
| WHITE | 292 | 293 | 306 | 106 | 0 | 0 | 0 | 997 |
Showing the first 100 of 214 sites across 20 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Jan 2019 to primary completion in Mar 2025, 74 months.
Results were first posted in Jun 2026, 1 year 2 months after primary completion.
Of 73 industry-sponsored phase 3 interventional studies under Ovarian Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 72. This study's 74 months is above that.
Counting every sponsor, half of 125 studies reached it within 59 months; a quarter within 37 and three quarters within 89.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Durvalumab · Olaparib